We have previously shown in anesthetized, open-chest dogs with coronary stenosis and endothelial injury that serotonin and/or thromboxane A2 (TXA2) receptor activation play a major role in the mediation of platelet-dependent, intermittent coronary occlusion. Using a similar model in awake, closedchest dogs, we tested the following hypotheses: 
Introduction
Platelet-mediated obstruction of stenotic coronary arteries may be an important mechanism in certain occlusive coronary disease states (1) (2) (3) (4) (5) (6) (7) (8) . We have previously demonstrated that serotonin (9) (10) (11) and thromboxane A2 (TXA2) (12) (13) (14) are important mediators of coronary occlusion due to platelet aggregation in anesthetized dogs with coronary artery stenoses and endothelial injury. Other factors may be important in governing the process of platelet aggregation at sites of coronary artery stenosis in awake, active animals. Although it is clear from in vitro studies of platelet aggregation that platelet agonists can act synergistically (15) , it is not known how frequently such mechanisms are functional in vivo (1 1, 16) . It has been shown in humans that circulating levels of catecholamines and TXB2, the stable metabolite ofTXA2, are elevated during periods of controlled exercise (17) . Circulating markers of platelet activation, platelet factor 4 and ,B thromboglobulin, have been shown to be elevated during periods of exercise-induced myocardial ischemia (18) . Other investigators, however, have failed to substantiate a link between exercise and platelet activation in patients with coronary disease (19) . Thus, it was our objective to evaluate the effect ofexercise on the induction of platelet aggregation and cyclical reductions in coronary blood flow in dogs with coronary artery stenoses and endothehial injury.
In the animal model that we used, described originally by Folts et al. (20) , a hard, plastic constrictor is placed around a canine coronary artery at the site of an induced endothelial injury. Within a few minutes, a unique pattern of coronary blood flow develops, characterized by severe, spontaneous reductions followed by abrupt, spontaneous restorations of flow. These recurrent reductions in coronary blood flow have been termed "cyclic flow variations" (CFVs)' and have been shown to result, at least in part, from the aggregation and subsequent dislodgement of occlusive platelet thrombi (3, 12, 21) . Agents specifically designed to inhibit platelet function, including serotonin receptor antagonists (9-1 1), TXA2 synthesis inhibitors (12) or receptor antagonists (13) , or MAbs to the platelet glycoprotein lIb/IlIa receptor (22) , prevent the occurrence of CFVs in most cases. Furthermore, histologic examination of coronary arteries obtained at the nadir ofcyclic flow variations consistently reveals an adherent platelet mass (12, 14, 20 Exercise protocol. After recovery from the surgical procedure was complete and dogs were able to walk comfortably, the effect of treadmill exercise on the development ofcyclic flow variations was tested in 11 dogs (Fig. 1) . Each dog was monitored at rest for 30 min while standing on a specially modified treadmill (Landace Treadmill Co., Dover, NJ). Baseline values for heart rates, blood pressures, and phasic and mean coronary blood flows were recorded. All dogs had stable, nonvarying coronary blood flows before exercise. At the end of30 min at rest, blood samples for the determination of plasma catecholamines were obtained from the arterial catheter. The treadmill was then started at 1-2 mph and maintained at this rate for 30 min. A period of treadmill exercise was designated as the time that the treadmill was in operation. The maximum heart rates, blood pressures, and coronary blood flows during treadmill exercise were recorded. If CFVs did not occur during the 30-min period oftreadmill exercise, the treadmill was stopped and observation continued at rest for 30 min. If CFVs were observed, treadmill exercise was continued while either a serotonin or TXA2 receptor antagonist was administered (see protocol below). The severity (nadir coronary blood flow) and frequency of CFVs was determined before and after treatment. A blood sample for catecholamine determination was obtained at the time CFVs developed or at the end of exercise, if CFVs did not occur.
Treatment of exercise-induced CFVs. To test the importance of serotonin, thromboxane A2 and/or alpha2-adrenergic receptor activation in the mediation of platelet-dependent reductions in coronary blood flow in awake, closed-chest, exercising dogs with coronary artery stenoses, we entered six dogs into the following treatment protocol. Exercise-induced CFVs were observed for 15 min while exercise continued to ensure the persistence of the altered flow state. Each dog was then randomly assigned to receive a drug from one of the following treatment groups. Louis, MO) (1.0 mg/kg), was administered as an intravenous bolus during exercise-induced reductions in coronary blood flow. The effect ofyohimbine on CFVs or persistent low flow was recorded as described previously for other agents. An additional dose was administered ifthe initial dose was unsuccessful. Exercise was continued for 15 min after drug administration and recuperation was observed for at least 1 h.
Plasma catecholamines. Blood samples for the determination of plasma epinephrine and norepinephrine were obtained from the arterial catheter and immediately centrifuged and the serum was separated. Plasma samples were analyzed using HPLC (Smith-Kline Biosciences, St. Louis, MO).
Statistical analyses. All values are expressed as the mean±SEM. The effect of ventricular pacing was analyzed using an analysis of variance with a correction for repeated measures. Values obtained before and after exercise and treatment were compared with a paired t test. Independent groups were compared with an unpaired t test. A general linear model procedure was used in the analysis of variables predictive of the development of CFVs in a given dog during pacing or exercise. A P value < 0.05 was considered significant.
Results
11 consecutive dogs underwent the initial operative procedure and all survived. The intraoperative heart rates, blood pressures, and coronary blood flows are recorded in Table I . The placement of the cylindrical constrictor around the left anterior descending coronary artery resulted in a 19% decrease in mean coronary blood flow, but it was not associated with any significant change in the heart rates or blood pressures. All 11 dogs developed spontaneous CFVs in the operating room. During CFVs in anesthetized, open-chest dogs, the mean coronary blood flow ranged from 98±5% control (peak) to 46±4% (nadir) at a frequency of 7.2±0.4 cycles per 30 min. After chest closure, all dogs experienced the gradual discontinuation of cyclic flow variations by 3 h after operation. The average coronary blood flow on the morning of the first postoperative day after stabilization was 94±8% of control.
Ventricular pacing. The effect of ventricular pacing was tested in 5 of 11 dogs (Table II) . There was a significant increase in phasic and mean coronary blood flow during maximal pacing. There was no significant increase in blood pres- Table I. sure during ventricular pacing. There was no significant change in the plasma epinephrine levels during maximal pacing ( Fig. 2 ) (89±22 vs. 77±64 pg/ml, P = NS, n = 5). Only one dog developed CFVs during ventricular pacing (Fig. 3) . At a maximal rate of 170 beats/min, this dog developed mild, though frequent, CFVs that completely disappeared when the rate was decreased to 150 beats/min. None of the other four dogs that were tested developed CFVs during any of 11 periods of ventricular pacing. Effect ofexercise. The effect of treadmill exercise on coronary blood flow, hemodynamics, and plasma catecholamines was tested in 11 dogs (Table III) . During the control period at rest, no spontaneous reductions in coronary blood flow were observed. Resting plasma epinephrine levels were not significantly different from dogs before pacing (102±47 vs. 89±22 pg/ml, P = NS). Treadmill exercise at 1-2 mph was associated with a significant increase in heart rates (123±5 to 153±6, P = 0.001), systolic blood pressures (122±3 to 137±2 mmHg, P = 0.05), and maximal coronary blood flow (97±6 to 125±8% VENTRICULAR PACING ioo serotonin receptor antagonist (n = 4), during episodes of exercise-induced reductions in coronary blood flow resulted in a greater than twofold increase in mean coronary blood flow (35±10 to 80±18% control, P = 0.01, n = 8). In four dogs with CFVs (average peak/nadir flow 105±12/50±15% control), SQ29548 resulted in a significant decrease in the frequency (7.75± 1.1 vs. 2.5±1.5 CFVs per 30 min, P = 0.05, n = 4) and severity (nadir flow increased to 87±28% control, n = 4) of CFVs (Fig. 6 ). In three of four dogs in whom CFVs deteriorated into a noncyclic pattern of persistent low coronary blood flow, SQ29548 caused a marked increase in coronary blood flow (22±6 to 74±27% control, P = 0.09, n = 4). In one dog with persistent low flow on postoperative day 7 and in one dog with CFVs on postoperative day 11 despite treatment with ketanserin, SQ29548 failed to substantially improve coronary blood flow. Administration of SQ29548 was not associated with any significant changes in heart rates (146±13 vs.
149+14, P = NS, n = 8) or mean blood pressures (94±8 vs.
97+6, P = NS, n = 8) ( Table V) .
The administration of a serotonin receptor antagonist, ketanserin (n = 3, average dose 0.42 mg/kg, range 0.25 to 0.50 mg/kg) or LY53857 (n = 6, average dose 0.23±0.05 range 0.2 to 0.4 mg/kg), during episodes of exercise-induced reductions in coronary blood flow resulted in a significant increase in mean coronary blood flow (32±9 to 49±13, P = 0.03, n = 9) (Fig. 7) . In four dogs with cyclic flow reductions (average peak/nadir mean flow 108±22/47±14% control), ketanserin (n = 1) or LY53857 (n = 3) resulted in a significant reduction in the frequency of CFVs (6.25±0.55 vs. 1.25±1.25, P = 0.05, n = 4) and in their severity (nadir flow increased to 81± 13% control, P = 0.07, n = 4). In two of five dogs with persistent (Fig. 8) Treatment with a serotonin receptor antagonist and/or a TXAJPGH2 receptor antagonist during exercise-induced reductions in coronary blood flow resulted in a twofold increase in minimum coronary blood flow (33±6 to 64±11% control, P = 0.001, n = 17). Episode, first, second, or third episode of exercise-induced reduction in coronary blood flow; type, CFV or low flow (Low); order, order of administration (1, first; 2, second). If exercise-induced reduction in coronary flow was not improved by treatment with the first agent (two doses), then a second agent was added. Minimum coronary flow, lowest coronary blood flow (mean) recorded during either CFVs or persistent low flow; before/after, before and after treatment; delta, change in minimum coronary blood flow after treatment; total, cumulative increase in coronary blood flow after treatment with either one or two drugs. 522 Eidt, Ashton, Golino, McNatt, Buja, and Willerson Before/after, treatment effect; AOS, systolic blood pressure; AOD, diastolic blood pressure; Phasic peak/nadir, highest and lowest phasic coronary blood flow recorded before and after treatment; frequency, number of CFVs per 30 min. During cases of persistent low flow, the same values were recorded for peak and nadir flows; P < 0.05 significant, paired t test.
marked effilux of TXB2, the stable metabolite of TXA2, from the coronary sinus after atrial pacing (32) . In animals, atrial pacing has been shown to potentiate the adhesion of platelets at sites of canine coronary stenosis as evidenced by microscopic assessment (33) . In this study, ventricular pacing, at rates comparable to those observed during treadmill exercise, resulted in demonstrable reductions in coronary artery blood flow in only one dog. Although the formation of small, hemodynamically insignificant platelet aggregates might go undetected in our model, this study suggests that in awake, unsedated dogs, ventricular pacing does not play a dominant role in promoting platelet aggregation at sites of coronary stenosis. Treadmill exercise, in the same dogs, resulted not only in increased heart rates, but also increased systolic blood pressures and increased plasma catecholamine levels. In vitro, epinephrine is known to be an important promotor of platelet activation, particularly in synergism with other agents, including ADP (34), thrombin (35), and/or collagen (36) . The effect of epinephrine on platelet activation is thought to be mediated through alpha2-adrenergic receptors on the platelet surface membrane (37) . Occupancy of the alpha2 receptors by epinephrine results in an increase in intracellular ionized Ca2' which is postulated to decrease the threshold for activation (38) . Epinephrine may also induce the appearance of fibrinogen receptors on the platelet surface membrane that may play an important interplatelet adhesive function (39) . Thus, increases in systemic epinephrine concentration may have contributed to platelet aggregation during exercise by stimulating alpha2 receptors on platelets and/or by contributing to vasoconstriction at sites ofcoronary artery stenosis and endothelial injury.
Using an animal model, it has been reported that epinephrine infusion exacerbates the severity of spontaneous CFVs in dogs with coronary artery stenoses (40) . Furthermore, epinephrine infusion has been shown to restore CFVs after their successful abolition with cyclooxygenase inhibition (20) , thromboxane synthesis inhibition (41), or serotonin receptor antagonism (41) . In this study, treadmill exercise resulted in the development of CFVs in all dogs, although not during every exercise period. Although yohimbine did not completely abolish exercise-induced reductions in coronary blood flow in any of four dogs, yohimbine did reduce the frequency of cyclic flow variations by nearly 50%. Other laboratories have reported the limited efficacy ofyohimbine in abolishing CFVs in anesthetized dogs (42) . In summary, the data from this study suggest that increases in circulating epinephrine may increase the likelihood of developing CFVs, but that alpha2-adrenergic receptor antagonism does not consistently prevent the occurrence of exercise-induced coronary blood flow reduction in this model. It is possible that platelet agonists other than epinephrine are of equal or greater importance locally at the site of coronary stenosis and endothelial injury.
Both treadmill exercise and pacing were associated with an increase in coronary blood flow before the onset of CFVs or low flow. It is possible that increased wall shear stress or turbulence may contribute to the development of CFVs.
In experiments from our laboratory, serotonin and TXA2 have been shown to cooperate in the mediation of CFVs in anesthetized, open-chest dogs with coronary stenoses (9) (10) (11) (12) (13) (14) . We have previously reported that serotonin receptor inhibition with ketanserin or LY53857 (9) (10) (11) or that inhibition of thromboxane synthesis (12), with dazoxiben, or TXA2 receptor activation, with SQ29548 (13) , abolishes CFVs in most dogs. The combination of serotonin and TXA2 receptor antagonism abolishes CFVs in virtually every case in anesthetized dogs (11) . We have also shown in anesthetized dogs that vasoconstriction resulting from the release of TXA2 and/or serotonin by activated platelets may contribute to decreased coronary blood flow (43) and that TXA2 and serotonin receptor antagonists prevent the coronary artery vasoconstriction associated with cyclic coronary flow alterations occurring in the anesthetized, open-chest dog (43) . In our previous studies, we have not been able to demonstrate that TXA2 or serotonin exert coronary vasoconstrictor effects at sites other than where platelets attach in excess numbers, i.e., at the coronary stenosis and at adjacent sites where endothelial injury coexists (43) . Furthermore, TXA2 and serotonin receptor antagonists generally prevent cyclic flow alterations and coronary vasoconstriction without altering systemic hemodynamics importantly. Our data suggest that TXA2 and serotonin cause CFVs primarily by promoting platelet aggregation and coronary vasoconstriction at the coronary stenosis and immediately adjacent sites (9) (10) (11) (12) (13) 43) . The treatment ofCFVs was substantially more successful than the treatment of persistent low coronary flow, suggesting a more durable obstruction at or near the site of coronary stenosis during periods of persistent low flow.
In summary, the evidence from the current study supports the following conclusions: (a) treadmill exercise in dogs promotes the development of CFVs in awake, closed-chest dogs with coronary stenosis and endothelial injury; (b) ventricular pacing does not consistently cause coronary blood flow reduction in the same model; and (c) serotonin and TXA2 are im-portant mediators of CFVs in this model. Alpha2-adrenergic receptor activation by circulating epinephrine may contribute to the aggregation of platelets in exercising dogs.
